XAIR
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Beyond Air, Inc.
- Nom
- Beyond Air, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $1.4M
- Employés
- 54
- PDG
- Robert Goodman
- Site web
- https://www.beyondair.net
- Marché
- AEONBOLTCLRBCODXIINNLFWD
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 34 722 titres (~199 998,72 $ US)
- Insiders
- Goodman Robert Scott
- Total bought
-
$199,999
Avg buy (VWAP, 90d window) $4.47 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-29
- Last synced
-
2026-10-19 22:07:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-13 | Lin Yi-Chien | Buy · P | 2,607 | $2.21 | $5,761 | Form 4 |
| 2026-10-01 | Lin Yi-Chien | Buy · P | 15,393 | $2.80 | $43,100 | Form 4 |
| 2026-09-30 | Lin Yi-Chien | Buy · P | 2,000 | $2.71 | $5,420 | Form 4 |
| 2026-09-29 | Lin Yi-Chien | Buy · P | 3,000 | $2.69 | $8,070 | Form 4 |
| 2026-07-29 | Goodman Robert Scott | Buy · P | 34,722 | $5.51 | $191,318 | Form 4 |
| 2026-07-29 | MOORHEAD DANIEL J | Buy · P | 4,340 | $5.51 | $23,913 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 3.80 · operating margin -378% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 3.3% | -44.9% | -112.8% | 0.0% | 0.0% | |
| Ebit Margin | -447.1% | -1227.0% | -5296.2% | 0.0% | 0.0% | |
| Ebitda Margin | -399.6% | -1130.6% | -5093.3% | 0.0% | 0.0% | |
| Operating Profit Margin | -378.2% | -1202.1% | -5436.2% | 0.0% | 0.0% | |
| Pretax Profit Margin | -447.1% | -1308.5% | -5547.5% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -447.1% | -1308.5% | -5547.5% | 0.0% | 0.0% | |
| Net Profit Margin | -433.0% | -1258.4% | -5197.8% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -433.0% | -1258.4% | -5197.8% | 0.0% | 0.0% | |
| Current Ratio | 3.804 | 3.204 | 3.798 | 3.004 | 8.677 | |
| Quick Ratio | 3.588 | 2.720 | 3.615 | 2.946 | 8.644 | |
| Solvency Ratio | -1.015 | -2.739 | -1.944 | -2.045 | -2.029 | |
| Cash Ratio | 1.035 | 0.933 | 0.984 | 1.474 | 7.491 | |
| Price To Earnings Ratio | -3.441 | -0.396 | -0.870 | -3.625 | -3.971 | |
| Price To Earnings Growth Ratio | 0.035 | 0.006 | 0.356 | -0.339 | -0.123 | |
| Forward Price To Earnings Growth Ratio | 0.035 | 0.006 | 0.356 | -0.339 | -0.123 | |
| Price To Earnings Diluted Ratio | -3.441 | -0.396 | -0.870 | -3.625 | -3.971 | |
| Price To Earnings Diluted Growth Ratio | 0.035 | 0.006 | 0.356 | -0.339 | -0.123 | |
| Price To Book Ratio | 18.699 | 1.358 | 2.092 | 5.336 | 2.358 | |
| Price To Sales Ratio | 14.918 | 4.980 | 45.205 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -5.976 | -0.418 | -0.848 | -5.485 | -6.995 | |
| Price To Operating Cash Flow Ratio | -6.314 | -0.483 | -0.935 | -6.129 | -7.412 | |
| Debt To Assets Ratio | 0.661 | 0.389 | 0.313 | 0.052 | 0.035 | |
| Debt To Equity Ratio | 3.817 | 0.860 | 0.712 | 0.095 | 0.048 | |
| Debt To Capital Ratio | 0.792 | 0.463 | 0.416 | 0.087 | 0.046 | |
| Long Term Debt To Capital Ratio | 0.779 | 0.404 | 0.370 | 0.003 | 0.003 | |
| Financial Leverage Ratio | 5.776 | 2.213 | 2.274 | 1.813 | 1.364 | |
| Working Capital Turnover Ratio | 0.525 | 0.171 | 0.032 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.787 | -7.644 | -4.843 | -1.669 | -2.160 | |
| Operating Cash Flow Sales Ratio | -2.363 | -10.315 | -48.330 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | 1.154 | 1.103 | 1.117 | 1.060 | |
| Debt Service Coverage Ratio | -76.521 | -11.546 | -15.903 | -72.299 | -25.086 | |
| Interest Coverage Ratio | 0.000 | -14.752 | -21.637 | -1,735.300 | -52.529 | |
| Short Term Operating Cash Flow Coverage Ratio | -45.247 | -62.755 | -70.019 | -42.592 | -24.956 | |
| Operating Cash Flow Coverage Ratio | -0.776 | -3.270 | -3.140 | -9.190 | -6.634 | |
| Capital Expenditure Coverage Ratio | -17.701 | -6.496 | -9.750 | -8.514 | -16.764 | |
| Dividend Paid And Capex Coverage Ratio | -17.701 | -6.496 | -9.750 | -8.514 | -16.764 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.276 | -0.608 | -0.997 | -3.037 | -2.218 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 3.3% | ▲48.2% | ▲34.2% |
| Ebit Margin | -447.1% | ▲779.9% | ▲947.0% |
| Ebitda Margin | -399.6% | ▲731.0% | ▲925.1% |
| Operating Profit Margin | -378.2% | ▲823.9% | ▲1025.1% |
| Pretax Profit Margin | -447.1% | ▲861.4% | ▲1013.5% |
| Continuous Operations Profit Margin | -447.1% | ▲861.4% | ▲1013.5% |
| Net Profit Margin | -433.0% | ▲825.5% | ▲944.8% |
| Bottom Line Profit Margin | -433.0% | ▲825.5% | ▲944.8% |
| Current Ratio | 3.804 | ▲0.600 | ▼-0.693 |
| Quick Ratio | 3.588 | ▲0.868 | ▼-0.715 |
| Solvency Ratio | -1.015 | ▲1.724 | ▲0.940 |
| Cash Ratio | 1.035 | ▲0.102 | ▼-1.348 |
| Price To Earnings Ratio | -3.441 | ▼-3.046 | ▼-0.981 |
| Price To Earnings Growth Ratio | 0.035 | ▲0.029 | ▲0.048 |
| Forward Price To Earnings Growth Ratio | 0.035 | ▲0.029 | ▲0.048 |
| Price To Earnings Diluted Ratio | -3.441 | ▼-3.046 | ▼-0.981 |
| Price To Earnings Diluted Growth Ratio | 0.035 | ▲0.029 | ▲0.048 |
| Price To Book Ratio | 18.699 | ▲17.341 | ▲12.731 |
| Price To Sales Ratio | 14.918 | ▲9.938 | ▲1.897 |
| Price To Free Cash Flow Ratio | -5.976 | ▼-5.558 | ▼-2.031 |
| Price To Operating Cash Flow Ratio | -6.314 | ▼-5.831 | ▼-2.059 |
| Debt To Assets Ratio | 0.661 | ▲0.272 | ▲0.371 |
| Debt To Equity Ratio | 3.817 | ▲2.957 | ▲2.711 |
| Debt To Capital Ratio | 0.792 | ▲0.330 | ▲0.432 |
| Long Term Debt To Capital Ratio | 0.779 | ▲0.376 | ▲0.468 |
| Financial Leverage Ratio | 5.776 | ▲3.563 | ▲3.088 |
| Working Capital Turnover Ratio | 0.525 | ▲0.354 | ▲0.379 |
| Operating Cash Flow Ratio | -2.787 | ▲4.857 | ▲1.034 |
| Operating Cash Flow Sales Ratio | -2.363 | ▲7.952 | ▲9.839 |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | ▼-0.097 | ▼-0.042 |
| Debt Service Coverage Ratio | -76.521 | ▼-64.975 | ▼-36.250 |
| Interest Coverage Ratio | 0.000 | ▲14.752 | ▲364.844 |
| Short Term Operating Cash Flow Coverage Ratio | -45.247 | ▲17.509 | ▲3.867 |
| Operating Cash Flow Coverage Ratio | -0.776 | ▲2.494 | ▲3.826 |
| Capital Expenditure Coverage Ratio | -17.701 | ▼-11.205 | ▼-5.856 |
| Dividend Paid And Capex Coverage Ratio | -17.701 | ▼-11.205 | ▼-5.856 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.276 | ▼-3.667 | ▼-2.048 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $114.6M | $18.4M | $52.4M | $202.3M | $171.5M | |
| Enterprise value | $131.2M | $25.5M | $58.9M | $176.8M | $94.7M | |
| EV / Sales | 17.09x | 6.88x | 50.78x | 0.00x | 0.00x | |
| EV / Op. cash flow | -7.23x | -0.67x | -1.05x | -5.36x | -4.09x | |
| EV / Free cash flow | -6.84x | -0.58x | -0.95x | -4.79x | -3.86x | |
| EV / EBITDA | -4.28x | -0.61x | -1.00x | -3.04x | -2.22x | |
| Net debt / EBITDA | -0.54x | -0.17x | -0.11x | 0.44x | 1.80x | |
| Current ratio | 3.80x | 3.20x | 3.80x | 3.00x | 8.68x | |
| Income quality | 0.55x | 0.79x | 0.93x | 0.56x | 0.54x | |
| Graham net-net | -$2 | -$41 | $74 | $270 | $933 | |
| Tax burden | 96.8% | 96.2% | 93.7% | 94.0% | 98.0% | |
| Interest burden | 100.0% | 106.6% | 104.7% | 100.1% | 101.8% | |
| Working capital | $18.3M | $11.0M | $32.4M | $39.6M | $82.2M | |
| Invested capital | $28.7M | $25.0M | $45.3M | $48.8M | $88.3M | |
| Return on assets | -94.0% | -155.1% | -105.8% | -81.2% | -43.5% | |
| Operating ROA | -88.8% | -102.4% | -100.2% | -62.0% | -58.3% | |
| Return on tangible assets | -96.7% | -161.7% | -108.5% | -83.2% | -44.3% | |
| Return on equity | -542.8% | -343.3% | -240.5% | -147.2% | -59.4% | |
| Return on invested capital | -98.1% | -170.9% | -135.2% | -103.9% | -45.4% | |
| Return on capital employed | -100.6% | -177.7% | -138.8% | -106.3% | -46.0% | |
| Earnings yield | -29.0% | -252.7% | -115.0% | -27.6% | -25.2% | |
| Free cash flow yield | -16.7% | -239.0% | -117.9% | -18.2% | -14.3% | |
| Capex / Op. cash flow | -5.6% | -15.4% | -10.3% | -11.7% | -6.0% | |
| Capex / Depreciation | 28.1% | 164.7% | 244.3% | 331.4% | 234.7% | |
| Capex / Sales | 13.3% | 158.8% | 495.7% | 0.0% | 0.0% | |
| SG&A / Sales | 248.1% | 702.2% | 3221.5% | 0.0% | 0.0% | |
| R&D / Sales | 133.4% | 455.0% | 2102.1% | 0.0% | 0.0% | |
| Stock comp / Sales | 68.8% | 246.9% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 2.9% | 4.1% | 2.5% | 2.4% | 1.9% | |
| Days sales outstanding | 57d | 85d | 173d | 0d | 0d | |
| Days payables outstanding | 119d | 133d | 288d | 1326d | 0d | |
| Operating cycle | 126d | 249d | 487d | 742d | 0d | |
| Cash conversion cycle | 7d | 116d | 199d | -583d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+520.9%EV / Sales ▲+148.5%EV / EBITDA ▼-603.1%EV / Op. cash flow ▼-6.564Earnings yield ▲+2.237
Profitability
Return on equity ▼-1.995Return on assets ▲+0.611Return on invested capital ▲+0.727Return on capital employed ▲+0.771Operating ROA ▲+0.136Income quality ▼-0.243Tax burden ▲+0.007
Efficiency
Days sales outstanding ▼-28.112Days payables outstanding ▼-13.808Operating cycle ▼-123.360Cash conversion cycle ▼-109.552Capex / Sales ▼-1.454R&D / Sales ▼-3.216
Balance-sheet strength
Current ratio ▲+0.600Net debt / EBITDA ▼-0.375Working capital ▲+7238000.000Invested capital ▲+3757000.000Intangibles / Total assets ▼-0.012
Change over 5 years
Valuation
Market cap ▼-33.2%EV / Sales n/aEV / EBITDA ▼-92.8%EV / Op. cash flow ▼-3.137Earnings yield ▼-0.038
Profitability
Return on equity ▼-4.834Return on assets ▼-0.504Return on invested capital ▼-0.527Return on capital employed ▼-0.546Operating ROA ▼-0.305Income quality ▲+0.010Tax burden ▼-0.012
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-4.873Net debt / EBITDA ▼-2.340Working capital ▼-63977000.000Invested capital ▼-59564000.000Intangibles / Total assets ▲+0.010
Employee count
Peer market caps
Recent news
- 2026-10-19 Duchess Restaurants Selects Beyond Oil as Frying Standard Across the Chain Homegrown Connecticut quick-service restaurant chain, serving diners since 1956, endorses Beyond Oil''s frying technology Homegrown Connecticut quick-service restaurant chain, serving diners since 1956, endorses Beyond Oil''s frying technology
- 2026-10-13 Beyond Oil Appoints Joe Colligan as Chief Executive Officer of Beyond Oil USA Commercial leader brings more than 30 years of experience at McCain Foods, Unilever and OSI Group Will work to accelerate North American expansion of Beyond Oil''s solution for safer, better and more profitable frying VANCOUVER, British Columbia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, today announced the appointment of Joe Colligan as Chief Executive Officer of its wholly owned operating subsidiary, Beyond Oil USA Inc. (“Beyond Oil USA”), effective October 26, 2026.
- 2026-10-08 Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026.
- 2026-09-02 Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026.
- 2026-08-31 Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD).
- 2026-08-25 Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments Beyond Air to receive shares representing 19.99% of Univo''s issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd (“UNIVO”) Univo Pharmaceutical Industries Ltd.
- 2026-08-13 Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript
- 2026-08-13 Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027
- 2026-08-04 Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026 GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced that it will report financial results for its quarter ended June 30, 2026 on Thursday, August 13, 2026. The Company''s management team is scheduled to host a conference call and webcast at 8:00 a.m. Eastern Time (ET) the same day.
- 2026-07-30 Beyond Oil Expands Commercial Rollout to a Second Ownership Group of Top-Tier U.S. Supermarket Brand VANCOUVER, British Columbia, July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, announces that, further to its news release dated March 30, 2026, it has been approved to expand its commercial rollout into another ownership group with 14 additional stores of a top-tier U.S. supermarket brand, ranked among North America''s top-30 food retailers by annual sales.1 Following the successful rollout with the first ownership group, Beyond Oil worked to fine-tune the program, ensure strong operator compliance and build an effective model for broader rollout.